Novel Boronic Chalcone Derivatives and Uses Thereof

Technical Details:  A class of anti-cancer agents such as chalcones has shown promising therapeutic efficacy for the management of human cancers. Recent studies have shown that anticancer agents such as chalcones induce apoptosis in variety of cell types, including breast cancers. Biochemical experiments showed that these compounds can disrupt the MDM2/p53 protein complex, releasing p53 from both the p53/MDM2 and DNA-bound p53/MDM2 complexes. However, these carboxylic acid analogs of chalcone are equally toxic to normal cells. In this proposal, a boronic-chalcone strategy is outlined that will overcome this limitation.

Looking for Partners:  The boronic-chalcones are more toxic to breast cancer cells compared to normal breast cells than other known chalcones. 
 
Patent Status: Granted US Patents 7,829,742 and 8,304,579
 
Associated Technology: See JHU Ref. 4085 for additional and distinct boronic-chalcone derivatives.
 
Associated Technology and Publications: See JHU Ref C04391 for additional Boronic Chalcone Derivatives; J Med Chem. 2003 Jul 3;46(14):2813-5. ;  Bioorg Med Chem. 2006 May 15;14(10):3491-5.

Category(s):